Sensors for Medical Device and Implantable Applications

 

醫療設備和植入式應用感測器

12月10日(二)

7:30 am Registration and Morning Coffee

Plenary Session

8:20 Chairperson's Remarks

Christopher Hartshorn, PhD, Program Director, Cancer Treatment & Diagnosis, National Institutes of Health; National Cancer Institute

8:30 Predictive Analytics in Digital Diagnostics for Management of Chronic Conditions

Rafael Carbunaru, PhD, Vice President R&D, Boston Scientific

9:00 Regulatory Considerations during Mobile Medical App Development for Commercial and Clinical Trial Use

Mike Benecky, Senior Director, Global Regulatory Affairs in Precision and Digital Medicine, GlaxoSmithKline

Mobile medical apps are defined as medical devices from their intended use. Mobile medical app regulation is health risk-based to balance patient safety and barriers to technological innovation. Medical device patient risk analysis is a critical prerequisite prior to sensor/app inclusion within a clinical trial. Key components of quality management systems for mobile medical apps include: software requirements/specifications, user acceptance testing, software postmarket surveillance, software version control, and medical device adverse event reporting.             

9:30 Nanotechnology, MEMS, Microfluidics for Health 4.0 Hypermobility

Ali Tinazli, PhD, Senior Director & Head, Healthcare & Life Sciences Strategy, Hewlett-Packard, HP Inc., CTO Office

New imperatives of healthcare are focusing on prevention, personalization of diagnostics and treatment, and democratization, including access to everyone, anywhere, anytime at a low cost. The technology convergence in medicine is enabled by the powerful combination of microelectronics, microfluidics, distributed network, and data analytics.

10:00 Networking Coffee Break

10:30 Roundtable Discussions

Next-Generation Wearable and Implantable Sensors

11:25 Chairperson's Remarks

Nick Van Helleputte, PhD, R&D Manager Biomedical Circuits & Systems, imec

11:30 Faults in Continuous Glucose Monitors: Cause, Effect, and Potential Solutions

Disha B. Sheth, PhD, Sr Staff Scientist, Manager, DexCom Inc.

Advancements in continuous glucose monitoring (CGM)- non-adjunctive use and zero calibrations- have been transformative for diabetes patients. Latest sensor technology and algorithms have resulted in sub-ten Mean Average Relative Differences (MARDs). However, there are some remaining difficult physiology related discrepancies. Complexity of immune responses, foreign body responses, patient to patient differences, and patch adhesion are causing inaccuracies. Drug-eluting sensors, multi-sensing elements, and self-learning algorithms are some of the potential solutions to these faults.

12:00 pm The Connected-Self Using Cloth-Based Nanotechnology: From R&D to Clinical Utility to Commercialization

Venk Varadan, Co-Founder and CEO, Nanowear

The early days of Connected-Self R&D could not overcome necessary efficacy and safety requirements in sufficient time to live up to the hype for medical use. After nearly ten years, there are specific technologies, products, and therapeutic areas that have emerged from this challenging phase of R&D, proving their value clinically and improving patient lives from the comfort of their own home

12:30 Sponsored Presentation (Opportunity Available)

1:00 Enjoy Lunch on Your Own

Next-Generation Wearable and Implantable Sensors (Cont.)

1:55 Chairperson's Remarks

Nick Van Helleputte, PhD, R&D Manager, Biomedical Circuits & Systems, imec

2:00 Non-Invasive Biochemical Sensing: Breakthrough for Precision Medicine

Gavi Begtrup, PhD, CEO, Eccrine Systems, Inc.

Today’s non-invasive electronic health patches perform conventional measures like heart activity and body motion, while the medical field awaits continuous wearable sensing of chemical information like that found in blood draws.  All this is now rapidly changing as sweat biosensing is targeting a first killer application in medication monitoring, enabling precision dosing through non-invasive, direct measurement of individual drug response.

2:30 The Customer behind the Customer/Sensor Design for Patient Usability

Grant Hughes, Co-Founder & Chief Strategy Officer, FocusMotion Health

In designing and implementing solutions, tech companies want to show off their bright shiny data, yet often forget the technology sophistication of the end user: the patient. Machine learning and millions of data points don't matter if we can't engage the patient or if we can't provide usable, actionable data for the surgeon or the hospital. How do we design to serve both customers?

3:00 FEATURED PRESENTATION: Leveraging AI to Improve Performance of Medical Sensors

Andrea Varsavsky, PhD, Senior Engineering R&D Manager, Medtronic Diabetes

With increased volumes of sensor data from medical sensors now available through their widespread use, more advanced analytics including machine learning can be utilized to derive algorithms that calculate the sensor outputs. In this presentation, we will describe how AI, large sensor databases and in-built diagnostics signals were leveraged to improve the accuracy of glucose sensors and greatly reduce user burden, without any changes in sensing technology.

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Tutorials

6:00 Welcome Reception in the Exhibit Hall with Poster Viewing

7:00 End of Day

12月11日(三)

8:00 am Registration and Morning Coffee

Plenary Session

8:20 Chairperson's Remarks

Robert Rubino, Senior Director, Research and Development, Integer

8:30 Dexcom's Continuous Glucose Monitoring (CGM) Technology and Its Impact on Diabetes Management, Artificial Pancreas, & Digital Health Systems

Peter Simpson, Vice President of Sensor R&D and Advanced Technology, Dexcom

Recent advances in continuous glucose monitoring (CGM) technology have significantly increased its usability and impact on diabetes management.  CGM's are now widely reimbursed and are rapidly becoming the standard of care for people on intensive insulin therapy.This presentation will provide an overview of Dexcom's CGM sensor technology, its use in digital health and artificial pancreas systems and a preview of our future products.

9:00 Objective Measures for Clinical Assessment and Precise Understanding of Disease Progression

Christopher Hartshorn, PhD, Program Director, Cancer Treatment & Diagnosis, National Institutes of Health; National Cancer Institute

This talk will look at various efforts across the National Institutes of Health attempting to enable more objective measures for out-of-clinic, patient-specific assessment and longitudinal understanding of disease progression in large cohorts.

9:30 Wearable Electrochemical Sensors - Recent Advances

Joseph Wang, Distinguished Professor & Chair, Nanoengineering, University of California, San Diego

This presentation will discuss recent developments in the field of wearable electrochemical sensors integrated directly on the epidermis or within the mouth for various non-invasive biomedical monitoring applications. Particular attention will be given to non-invasive monitoring of metabolites and electrolytes using flexible amperometric and potentiometric sensors, respectively, along with related materials, energy and integration considerations. The preparation and characterization of such wearable electrochemical sensors will be described, along with their current status, future prospects, and challenges. 

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

10:30 Roundtable Discussions

Clinical vs. Consumer Sensors

11:25 Chairperson's Remarks

Joshua Windmiller, PhD, MSc, Co-Founder & CTO, Biolinq, Inc.

PANEL DISCUSSION

11:30 The Medical Sensor Technologist's Dilemma - Clinical or Consumer Sensor

Panel Moderator:

Joshua Windmiller, PhD, MSc, Co-Founder & CTO, Biolinq, Inc.

Patient outcomes and standardization of care continue to benefit from smarter and sensor-enabled medical devices that provide real-time patient monitoring and device performance data. The challenge is selecting the right sensor, including deciding between consumer or clinical-grade sensors. This panel will evaluate the tradeoffs between these two sensor classes as the panelists tackle this dilemma.

Panelists:

Tom Calef, CTO, Activ Surgical

YuFeng Yvonne Chan, MD, PhD, Associate Professor & Director Digital Health, Genetics & Genomic Sciences & Emergency Medicine, Icahn School of Medicine at Mount Sinai

12:30 pm Sponsored Presentation (Opportunity Available)

1:00 Enjoy Lunch on Your Own

Ingestible and Insertable Sensors

1:55 Chairperson's Remarks

Joshua Windmiller, PhD, MSc, Co-Founder & CTO, Biolinq, Inc.

2:00 Turning on the Lights - Improving Outcomes and Increasing Access with Digital Medicines

Jeremy Frank, PhD, Senior Vice President Digital Medicine, Digital Medicine, Proteus Digital Health

The cost of sub-optimal pharmacotherapy is immense - 125,000 lives and over $500 billion annually in the US alone.  Poor patient adherence to prescriptions dominate that expense and current ineffective mitigation efforts do not address the fundamental root cause - the gap between physician expectation and patient behavior.  The Proteus digital-medicine platform integrates medication with hardware, software, analytics and services to close that critical loop.

2:30 Advancing Diagnostics in Endoscopy: Quantifying Inflammation through Perfusion Sensing

George Duval, Principal Engineer, Endoscopy R&D, Boston Scientific Corp.

Inflammation is the root of a lot of digestive diseases like Ulcerative Colitis, Barrett’s Esophagus, and more. With today’s tools, gastroenterologists using direct visual observations are very subjective to interpretation. The desire to quantify inflammation objectively during an examination could mean improved patient outcomes and procedures. We have been researching a variety of sensing technologies that show promise in quantifying inflammation. 

3:00 Ingestible and Insertable Technology for Advanced Monitoring of the GI System

Nick Van Helleputte, PhD, R&D Manager, Biomedical Circuits & Systems, imec

Globally metabolic health is dropping at an alarming rate. The human gastro-intestinal system is a very complex system and actually rather accessible, certainly considering recent technological advances in sensing and miniaturization. This talk will focus on technological innovations needed to provide a holistic view of the human GI system in the form of ingestibles or minimally invasive insertables.

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Tutorials

6:00 End of Day

* 活動內容有可能不事先告知作更動及調整。

Choose your language
Chinese
Japanese
Korean
English









免費電子郵件通知服務